RESUMEN
Preeclampsia (PE) is a pregnancy disorder that may be associated with inadequate maternal nutrition. Fatty acids are vital for placental and fetal growth. Fatty acid desaturases, key enzymes influencing the metabolism of polyunsaturated fatty acids, are reported to be associated with cardiometabolic risk. Any imbalance in the levels of omega-3 and omega-6 fatty acids can result in increased inflammatory response. The current study reports the levels of erythrocyte fatty acids and desaturase index across gestation in women who develop PE (n = 108) and compares them with non-PE women (n = 216). Maternal erythrocyte fatty acids were measured at 4 time points during pregnancy (i.e., 11-14, 18-22, 26-28 weeks and at delivery) using gas chromatography. Maternal total erythrocyte saturated fatty acids and omega-6/omega-3 fatty acid ratio was higher in the PE group as compared to the non-PE group at 11-14 weeks and 18-22 weeks respectively. Maternal Δ5 desaturase index was lower while Δ6 desaturase index was higher in the PE group at 11-14 and 18-22 weeks. Maternal stearoyl CoA desaturase-18 (SCD-18) index was lower at 11-14 weeks and at delivery. These changes were mainly observed in the early onset PE (EOP) group. Δ6 desaturase index at 11-14 weeks predicted the risk of EOP. Imbalance in fatty acid levels and desaturase indices predate the clinical diagnosis of PE, indicating their role in its pathophysiology. Measurement of fatty acids and desaturase indices in early pregnancy merits evaluation as predictors of risk of PE.
Asunto(s)
Ácidos Grasos Omega-3 , Preeclampsia , Femenino , Humanos , Embarazo , Ácidos Grasos/metabolismo , Preeclampsia/metabolismo , Placenta/metabolismo , Ácido Graso Desaturasas/metabolismo , Estearoil-CoA Desaturasa , Ácidos Grasos Omega-3/metabolismo , Eritrocitos/metabolismo , Linoleoil-CoA Desaturasa/metabolismoRESUMEN
Background. Efficacy of standard dose of primaquine (PQ) as antirelapse for P. vivax has decreased. We aimed to assess efficacy of different PQ regimens. Methods. It was an open label, randomized, controlled, parallel group, assessor blind study comparing antirelapse efficacy of 3 PQ regimens (B = 15 mg/day × 14 days, C = 30 mg/day × 7 days, and D = 30 mg/day × 14 days) with no PQ group (A) in P. vivax patients. Paired primary and recurrence samples were subjected to 3 methods: (i) month of recurrence and genotyping, (ii) by PCR-RFLP, and (iii) PCR sequencing, to differentiate relapse and reinfection. The rates of recurrence relapse and reinfection were compared. Methods were compared for concordance between them. Results. The recurrence rate was 16.39%, 8.07%, 10.07%, and 6.62% in groups A, B, C, and D, respectively (P = 0.004). The relapse rate was 6.89%, 1.55%, 4%, and 3.85% as per the month of recurrence; 8.2%, 2%, 4.58%, and 3.68% (P = 0.007) as per PCR-RFLP; and 2.73%, 1.47%, 1.55%, and 1.53% as per PCR sequencing for groups A, B, C, and D, respectively. The concordance between methods was low, 45%. Conclusion. The higher recurrence rate in no PQ as compared to PQ groups documents PQ antirelapse activity. Regimens tested were safe. However, probable resistance to PQ warrants continuous monitoring and low concordance and limitations in the methods warrant caution in interpreting.
RESUMEN
Pseudo-pseudo Meigs' syndrome (PPMS) is a rare manifestation of patients with systemic lupus erythematosus (SLE), defined by the presence of ascites, pleural effusions and an elevated CA-125 level. We describe a patient with longstanding lupus who presented with localized lymphadenopathy and subsequently developed massive chylous ascites with marked hypoalbuminemia. A brief historical overview of Meigs' syndrome and related entities is presented, along with a discussion of the differential diagnosis of hypoalbuminemia and ascites in an SLE patient. In addition, we speculate on the optimal therapeutic intervention in such a patient.
Asunto(s)
Ascitis Quilosa/etiología , Lupus Eritematoso Sistémico/complicaciones , Derrame Pleural/etiología , Biomarcadores/sangre , Biopsia , Antígeno Ca-125/sangre , Ascitis Quilosa/diagnóstico , Ascitis Quilosa/terapia , Diagnóstico Diferencial , Femenino , Humanos , Hipoalbuminemia/etiología , Inmunosupresores/uso terapéutico , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/terapia , Enfermedades Linfáticas/etiología , Síndrome de Meigs/diagnóstico , Persona de Mediana Edad , Paracentesis , Derrame Pleural/diagnóstico , Derrame Pleural/terapia , Valor Predictivo de las Pruebas , Síndrome , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Regulación hacia ArribaRESUMEN
PURPOSE: Many isolates of Serratia marcescens, a well-known opportunistic pathogen, can be multidrug resistant. Fluoroquinolones are among the most important groups of antibiotics used for treatment of these organisms. However, fluoroquinolone resistance among S. marcescens isolates is fast increasing. Drug extrusion through efflux pumps like SdeAB/ HasF is one of the major mechanisms of resistance to fluoroquinolones. This study was carried out to analyze, through gene expression analysis of sdeB, the relative contribution of this mechanism toward fluoroquinolone resistance in clinical isolates of Serratia. MATERIALS AND METHODS: Total RNA from 45 clinical isolates of S. marcescens was isolated. Quantitative real-time RT PCR was performed on the extracted RNA to study the gene expression of sdeB and was normalized to the sdeB expression in the standard strain of S. marcescens. RESULTS: Of the 45 isolates analyzed, sdeB expression was found to be elevated in 20 isolates (44%). Of these 20 isolates, eight (40%) were fully resistant to at least one of the fluoroquinolones studied. Conversely, of the 20 isolates that over-expressed sdeB, 12 (60%) were fully sensitive to all fluoroquinolones tested. CONCLUSIONS: Drug efflux pumps are an important means of fluoroquinolone resistance among clinically important species of Serratia. The expression of these pumps can be up-regulated in the presence of antibiotics and have the potential for changing the phenotype from sensitive to resistant, thus contributing to therapeutic failures.
Asunto(s)
Farmacorresistencia Bacteriana Múltiple , Fluoroquinolonas/farmacología , Perfilación de la Expresión Génica , Proteínas de Transporte de Membrana/biosíntesis , Proteínas de Transporte de Membrana/genética , Serratia marcescens/efectos de los fármacos , Serratia marcescens/genética , Antibacterianos/metabolismo , Antibacterianos/farmacología , Fluoroquinolonas/metabolismo , Humanos , Reacción en Cadena en Tiempo Real de la Polimerasa , Infecciones por Serratia/microbiología , Serratia marcescens/aislamiento & purificaciónRESUMEN
OBJECTIVES: To determine the outcome, seasonal variation, and death pattern of snakebite cases admitted at the tertiary health care centre in the last 10 years. METHODS: This was a record-based retrospective descriptive study at the Dr Shankarrao Chavan Government Medical College and Hospital in Vazirabad, a tertiary health care centre in Maharashtra, India. RESULTS: Out of 5 639 admitted snakebite cases, 65.24% were male. The 16 - 45-year age group accounted for 84.7% of cases; 46% were referred from other health centres, mostly from rural areas; 55.2% occurred during July to September, which coincided with the rainy season in this region; 94.6% of the snakebite patients survived; and 5.4% died. Case fatality rates were higher for females (8.78%) and for bites by neurotoxic snakes (8.91%). CONCLUSIONS: Snakebite is a common life-threatening emergency in the study area. Ready availability and appropriate use of antivenom, early referral when required and close monitoring of patients in the hospital will help to reduce mortality from snakebites.
Asunto(s)
Mordeduras de Serpientes/epidemiología , Adolescente , Adulto , Antivenenos/uso terapéutico , Urgencias Médicas , Femenino , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico , Prevalencia , Pronóstico , Mordeduras de Serpientes/mortalidadAsunto(s)
Técnicos Medios en Salud/estadística & datos numéricos , África del Sur del Sahara , Técnicos Medios en Salud/educación , Técnicos Medios en Salud/tendencias , Humanos , India , Servicios de Salud Rural/estadística & datos numéricos , Servicios Urbanos de Salud/estadística & datos numéricos , Recursos HumanosRESUMEN
A community based cross sectional study was carried out in married reproductive age group women in Urban Health Centre field practice area of Govt. Medical College, Aurangabad. The study aimed to find out extent and socio-demographic correlates of unmet need for family planning. 20.54% of married women in reproductive age had unmet need for contraception, 3.61% for spacing births and 16.93% for limiting births. The main reasons for unmet needwere, littie perceived risk of pregnancy due to perimenopausal age (32.471/o) lactation (31.16%), ignorance (12.32%) etc.
Asunto(s)
Servicios de Salud Comunitaria/organización & administración , Anticoncepción/estadística & datos numéricos , Servicios de Planificación Familiar , Conocimientos, Actitudes y Práctica en Salud , Necesidades y Demandas de Servicios de Salud , Adolescente , Adulto , Femenino , Humanos , India , Persona de Mediana Edad , Clase Social , Población UrbanaRESUMEN
BACKGROUND: The WHO recommends that adults with uncomplicated P. falciparum successfully treated with a blood schizonticide receive a single dose of primaquine (PQ) 45 mg as a gametocytocidal agent. An earlier pilot study suggested that 75 mg of bulaquine (BQ), of which PQ is a major metabolite, may be a useful alternate to PQ. METHODS: In a randomized, partial blind study, 90 hospitalized adults with Plasmodium falciparum malaria that was blood schizonticide-responsive and a gametocytemia of > 55/microl within 3 days of diagnosis were randomized to receive single doses of either PQ 45 mg or BQ 75 mg on day 4. We assessed gametocytemia on days 8, 15, 22 and 29 and gametocyte viability as determined by exflagellation (2 degrees end point) on day 8. RESULTS: On day 8, 20/31 (65%) primaquine recipients versus 19/59 (32%) bulaquine recipients showed persistence of gametocytes (P = 0.002). At day 15 and beyond, all patients were gametocyte free. On day 8, 16/31 PQ and 7/59 BQ volunteers showed gametocyte viability (p = 0.000065). CONCLUSION: BQ is a safe, useful alternate to PQ as a Plasmodium falciparum gametocytocidal agent and may clear gametocytemia faster than PQ.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Primaquina/análogos & derivados , Primaquina/uso terapéutico , Adolescente , Adulto , Anciano , Animales , Antimaláricos/administración & dosificación , Doxiciclina/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Malaria Falciparum/parasitología , Masculino , Persona de Mediana Edad , Parasitemia/tratamiento farmacológico , Parasitemia/parasitología , Primaquina/administración & dosificación , Primaquina/farmacología , Quinina/administración & dosificación , Factores de Tiempo , Resultado del TratamientoRESUMEN
The efficacy of a single dose of 45 mg primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe Plasmodium falciparum malaria. All the patients investigated had been found gametocytaemic, with at least 56 gametocytes/microl blood, within the first 72 h of their illness. Those with uncomplicated malaria, like those with severe malaria, were randomized to receive or not receive primaquine. All the patients were followed up for 29 days post-admission, for gametocytaemia and gametocyte viability (as determined by exflagellation). Among those with uncomplicated malaria, six (27.3%) of the 22 who did not receive primaquine but only one (4.2%) of the 24 who did receive the drug, on day 4, remained gametocytaemic on day 29 (P < 0.05). Similarly, seven (31.8%) of the 22 severe cases who did not receive primaquine but only two (9.5%) of the 21 severe cases who received the drug, on day 8, were found gametocytaemic on day 15 (P < 0.05). While the single, 45-mg dose of primaquine recommended by the World Health Organization was effective in clearing gametocytes from the blood of > 90% of the present cases of malaria, > 4% of the patients with uncomplicated malaria and > 9% of those with the severe disease continued to harbour gametocytes in their peripheral blood 29 and 15 days after taking the primaquine, respectively.
Asunto(s)
Antimaláricos/administración & dosificación , Malaria Falciparum/tratamiento farmacológico , Primaquina/administración & dosificación , Adolescente , Adulto , Anciano , Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Malaria Falciparum/parasitología , Masculino , Persona de Mediana Edad , Parasitemia/tratamiento farmacológico , Primaquina/uso terapéutico , Estudios Prospectivos , Quinina/uso terapéuticoRESUMEN
OBJECTIVES: The present study compared the diagnostic and prognostic utility of two rapid tests the (Paracheck and OptiMal) versus conventional smear microscopy. METHODS: Using two independent microscopists we carried out the three tests in 31 adult cases of smear positive, acute, uncomplicated Plasmodium falciparum malaria. All three tests were done pretreatment, and on Days 8, 15 and 29. RESULTS: Compared to microscopy, the Paracheck had a sensitivity of 100%, while the OptiMal had a sensitivity of 83.7%. The lower sensitivity of OptiMal resulted from misidentification by both microscopists of 6/31 cases as Plasmodium vivax. As a follow up tool, the OptiMal was better than Paracheck, due to the earlier disappearance of the parasite LDH. Also in the Paracheck, between microscopists, there was a significant difference in reading the tests, on Days 8 and 15. CONCLUSION: Our study reiterates, the continued utility of conventional smear microscopy.
Asunto(s)
L-Lactato Deshidrogenasa/análisis , Malaria Falciparum/diagnóstico , Malaria Falciparum/patología , Plasmodium falciparum/aislamiento & purificación , Proteínas/análisis , Proteínas Protozoarias/análisis , Pruebas Serológicas/métodos , Adolescente , Adulto , Animales , Estudios Transversales , Femenino , Humanos , Masculino , Tamizaje Masivo/métodos , Persona de Mediana Edad , Plasmodium falciparum/enzimología , Valor Predictivo de las Pruebas , Juego de Reactivos para Diagnóstico , Sensibilidad y EspecificidadRESUMEN
The objective of the study was to compare the bioavailability of a single oral 200-mg dose of four brands of phenytoin sodium available in the Indian market. Dilantin, Epsolin, and M-toin were compared with Eptoin, which was taken as the reference standard. A randomized, assessor-blind, four-way crossover study was done in 12 healthy Indian volunteers. The study was conducted at a clinical pharmacology ward at King Edward VII Memorial Hospital, a tertiary referral center in Mumbai (Bombay). All 12 subjects received a single oral 200-mg dose of all the formulations with a 2-week washout period between the formulations. Blood samples for plasma phenytoin levels were collected at 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours. Safety was measured by pretreatment and posttreatment biochemical investigations, physical examination, and ECG. The pharmacokinetics of the four brands of phenytoin were calculated by maximum plasma concentration (C(max)), time to reach C(max) (t(max)), area under the concentration versus time curve for time 0 to 72 hours (AUC(0-72)), and from time 0 to infinity (AUC(0- infinity)). For all brands, 90% CI of all untransformed and log transformed pharmacokinetic parameters failed to remain within prescribed limits of 80% to 120% for untransformed data and 80% to 125% for log transformed data. Since phenytoin obeys Micheles Mentens kinetics, the AUC methodology used for comparison would give only an approximate indication of relative bioavailability. M-toin was shown to be bioinequivalent to Eptoin. The other comparisons indicate but do not prove bioinequivalence of the other brands. The results of the study show that in India switching phenytoin brands could have significant implications and is not advisable once a patient is carefully titrated on one formulation.
Asunto(s)
Anticonvulsivantes/farmacocinética , Fenitoína/farmacocinética , Adulto , Anticonvulsivantes/efectos adversos , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Humanos , India , Fenitoína/efectos adversos , Valores de Referencia , Método Simple Ciego , Equivalencia Terapéutica , Factores de TiempoRESUMEN
We studied the antirelapse efficacy of a supervised 14-d 15 mg/d regimen of primaquine therapy (n = 131) compared with no antirelapse therapy (n = 142) in 273 patients with confirmed Plasmodium vivax malaria in Mumbai, India, between July 1998 and April 2000. There were 6/131 (4.6%) recurrences in patients given primaquine compared with 13/142 (9.2%) in those not given antirelapse therapy. In the 14-d primaquine group, polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) genotyping analysis of pre- and post-treatment blood samples was done for the 6 patients who had a recurrence of parasitaemia and the results gave a true relapse rate of 2.29% (3/131), 2 samples were classified as reinfections and 1 sample did not amplify. Our results indicate probable resistance to the 14-d regimen of primaquine for the first time in India and illustrate the need to (i) monitor patients given this regimen and (ii) carry out comparative studies between primaquine and new drugs such as tafenoquine and bulaquine for preventing relapses.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Vivax/prevención & control , Primaquina/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Resistencia a Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Parasitemia/prevención & control , Plasmodium vivax/efectos de los fármacos , Reacción en Cadena de la Polimerasa/métodos , Polimorfismo Conformacional Retorcido-Simple , Recurrencia , Método Simple Ciego , Resultado del TratamientoRESUMEN
BACKGROUND: Malaria is a major public health problem representing 2.3% of the overall global disease burden. The cost of treatment of malaria continues to rise as older drugs and insecticides become less effective and are replaced by more effective, but also more expensive products. METHODS: A post-hoc pharmacoeconomic analysis (direct and indirect costs only) of three antimalarials, chloroquine, mefloquine and co-artemether, was carried out to address the problem of switch to a more expensive first-line antimalarial in the face of growing chloroquine resistance. RESULTS: From the perspective of a large public hospital, it was seen that in an area of high grade chloroquine resistance, the total expenditure on patients who fail chloroquine would exceed the excess expenditure on mefloquine when the RII + RIII resistance exceeded 9%. CONCLUSIONS: Switch to a more expensive drug like mefloquine as a first-line option would be cost-effective when the moderate-severe chloroquine resistance exceeded 9%.
Asunto(s)
Antimaláricos/economía , Hospitalización/economía , Malaria Falciparum/economía , Antimaláricos/uso terapéutico , Combinación Arteméter y Lumefantrina , Artemisininas/economía , Artemisininas/uso terapéutico , Cloroquina/economía , Cloroquina/uso terapéutico , Ensayos Clínicos como Asunto/economía , Análisis Costo-Beneficio , Combinación de Medicamentos , Economía Farmacéutica , Etanolaminas , Femenino , Fluorenos/economía , Fluorenos/uso terapéutico , Humanos , India , Malaria Falciparum/tratamiento farmacológico , Masculino , Mefloquina/economía , Mefloquina/uso terapéutico , Sesquiterpenos/economía , Sesquiterpenos/uso terapéuticoRESUMEN
Non-allopathic Indian medicines, referred to elsewhere in the world as complementary and alternative medicine have gathered increasing recognition in recent years with regard to both treatment options and health hazards. Ayurveda, Siddha, Unani and homeopathy are practiced in India as non-allopathic systems. These systems comprise a wide range of therapeutic approaches that include diet, herbs, metals, minerals, precious stones and their combinations as well as non-drug therapies. Ayurveda is the oldest system of medicine in the world and by far the most commonly practiced form of non-allopathic medicine in India, particularly in rural India, where 70% of the population lives. The difference between modern medicine and these systems stems from the fact that the knowledge base of many of the above systems, unlike Western medicine, is based on years of experience, observations, empiricism and intuition and has been handed down generations both through word of mouth and treatises. The focus on non-allopathic systems of medicine in India can be attributed to various causes including a need to revive a rich tradition, the dependency of 80% of the country's population on these drugs, their easy availability, increasing worldwide use of these medicines, the lack of focused concerted scientific research and the abuse of these systems by quacks. Elsewhere, the increasing use of herbal products worldwide and the growth of the herbal product industry has led to increasing concern regarding their safety. The challenges in these non-allopathic systems relate to the patient, physician, regulatory authorities, the abuse/misuse of these medicines, quality and purity issues. Safety monitoring is mandated by a changing ecological environment, the use of insecticides, new manufacturing techniques, an as yet unregulated pharmaceutical industry, the availability of combinations of herbs over the counter and not mentioned in ancient Ayurvedic texts, and the need to look at the active principles of these medicines as potential chemotherapeutic agents. The Indian traditional medicine industry has come a long way from the times when it was considered unnecessary to test these formulations prior to use, to the introduction of Good Manufacturing Practice guidelines for the industry. However, we still have a long way to go. The conflict between the traditional practitioners and the purists demanding evidence of safety and efficacy needs to be addressed. There is an urgent need for the practitioners of the allopathic and non-allopathic systems to work together to optimise the risk-benefit profile of these medicines.
Asunto(s)
Medicina Ayurvédica , Medicina Tradicional , Plantas Medicinales/efectos adversos , Ensayos Clínicos como Asunto/normas , Humanos , India , Metales Pesados/efectos adversos , Relaciones Médico-Paciente , Guías de Práctica Clínica como Asunto , Medición de RiesgoAsunto(s)
Centros Médicos Académicos , Industria Farmacéutica , Propiedad Intelectual , Investigación , Humanos , PolvosRESUMEN
Therapeutic Drug Monitoring (TDM) was introduced in India in the mid and late 1980s and the last 10 years have seen it grow, together with the growth of separate Clinical Pharmacology departments. The TDM service in the country is broadly of two types: in large teaching hospitals where the service is available through departments of Clinical Pharmacology, and in the private sector, where drug estimations are done by clinical biochemistry departments with minimal interpretation. This article is based on literature review and our own experiences over a 10 year period in a department of Clinical Pharmacology. It focuses on the evolution of TDM, its problems such as lack of funding, special aspects such as the impact of ethnic differences, nutritional deficiencies, quality of medicines and availability of generic products; its utility as a research tool and its future.
Asunto(s)
Países en Desarrollo , Monitoreo de Drogas/métodos , Farmacología Clínica/organización & administración , Monitoreo de Drogas/tendencias , Humanos , IndiaRESUMEN
AIMS: To carry out a retrospective pharmacoeconomic analysis of the impact of therapeutic drug monitoring (TDM) in adult patients with generalized tonic-clonic epilepsy in an academic, non profit making organization. METHODS: Twenty-five patients who had undergone TDM were compared with 25 age, disease and duration of drug therapy matched controls who had not undergone TDM. Only direct costs were calculated. These included cost to the hospital of providing the TDM service, cost to the hospital per seizure saved, and cost to the patient per seizure saved. RESULTS: Patients undergoing TDM had much more effective seizure control (P = 0.00032, OR 4.846, 95% confidence interval 1.29,18.3), fewer adverse events, better earning and were more likely to be married than the control group. CONCLUSIONS: In patients with adult onset epilepsy, a minimum of two drug estimations per year offers significant benefit in terms of better seizure control, fewer adverse events and greater chances of remission.